ARK Genomic Revolution ETF (ARKG)
About ARK Genomic Revolution ETF (ARKG)
The Fund is an actively managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80 percent of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the Funds investment theme of the genomics revolution (Genomics Revolution Companies). Under normal circumstances, substantially all of the Funds assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The Funds investments will include micro-, small-, medium- and large-capitalization companies. The Funds investments in foreign equity securities will be in both developed and emerging markets.
Details
ARK Genomic Revolution ETF News
Details
Exchange Traded Funds (ETFs): Investors should carefully consider the information contained in the prospectus, which contains the Fund’s investment objectives, risks, charges, expenses, and other relevant information. You may obtain a prospectus from the Fund company’s website. Please read the prospectus carefully prior to investing.
Shares of ETFs must be bought and sold at market price, which can vary significantly from the Fund’s net asset value (NAV). Investment returns are subject to market volatility and shares may be worth more or less their original value when redeemed. The diversification of an ETF will not protect against loss. An ETF may not achieve its stated investment objective. Rebalancing and other activities within the fund may be subject to tax consequences.
Performance data quoted represents past performance. Past performance does not guarantee future results. Investment returns and principal value of an investment will fluctuate and when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the standardized performance data quoted. Select the Standardized Performance link for the latest quarterly performance.